ArticleAnalytical chemistry2026
MetaboGraph: A Framework for Metabolomics and Lipidomics Annotation and Pathway Network Analysis.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MetaboGraph: A Framework for Metabolomics and Lipidomics Annotation and Pathway Network Analysis.Analytical chemistry · 2026Article
- Metabolic Remodeling of the Parkinson's Disease Frontal Cortex Revealed by LC-MS/MS Metabolomics.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Untargeted metabolomics and lipidomics generate high-dimensional data sets whose biological interpretation remains challenging, particularly at the pathway and network levels. Here, we present MetaboGraph, a standalone Python-based workflow for end-to-end metabolomics and lipidomics analysis, enabling pathway-level interpretation from small-molecule data. MetaboGraph integrates automated data cleaning, comprehensive multidatabase metabolite and lipid annotation, pathway mapping, and direction-aware pathway inference. A central feature of the platform is its ability to predict pathway direction by integrating metabolite/lipid-level fold changes with pathway membership structure, supporting biologically interpretable pathway and network analyses beyond conventional enrichment approaches. MetaboGraph supports multiomics integration and comparative analysis, enabling consistent pathway-level interpretation across metabolomics, lipidomics, and multiple studies. We demonstrate the platform using untargeted LC-MS/MS metabolomics and lipidomics data comparing two breast cancer cell lines with distinct metastatic potential, MCF7 (HTB22; less metastatic) and MDA-MB-453 (HTB131; more metastatic). Relative to HTB22, the HTB131 cells exhibited coordinated metabolic remodeling, including altered amino acid and nitrogen metabolism, increased nucleotide biosynthetic demand, lipid remodeling, and changes in energy-associated pathways. These pathway-level alterations are consistent with established metabolic adaptations associated with increased cancer aggression. MetaboGraph expands the analytical toolbox for small-molecule biology and facilitates reproducible, biologically grounded insights from metabolomics and lipidomics data sets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.